Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty

Last updated: July 20, 2021
Sponsor: Mayo Clinic
Overall Status: Completed

Phase

2/3

Condition

Knee Injuries

Osteoarthritis

Treatment

N/A

Clinical Study ID

NCT03838874
18-008635
  • All Genders

Study Summary

This research is being done to see if there is a difference between two different spinal anesthetics (Mepivacaine vs. Bupivacaine) as it relates to reducing post-operative complications and the time it takes for subjects to regain mobility after surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) physiological status I-III (patient mustmeet criteria of a status I-III in the ASA Physical Status Classification System:I=Normal Healthy Patient, II=Mild Systemic Disease, and III=Severe Systemic Disease)
  • Unilateral primary TKA or THA
  • 18+ years of age
  • Able to provide informed consent

Exclusion

Exclusion Criteria:

  • Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome
  • Chronic opioid use (>1 mos) with OME >5 mg/day OR acute opioid use (< 1 mos) with OME > 30 mg/day.
  • Body mass index (BMI) > 45 kg/m2
  • Severe drug allergy* to medications used in this study, including non-steroidalanti-inflammatory drugs (i.e. celecoxib and ketorolac), and local anesthetics (definedas an immune reaction resulting in shortness of breath, hives, anaphylaxis, wheezing,and fever)
  • Major systemic medical comorbidities such as:
  • Pre-existing severe renal disorder defined as glomerular filtration rate (GFR) <50 units/m2 (if labs are available), currently on dialysis, or highly suspectedbased on history.
  • Severe hepatic disorder defined as current or past diagnosis of acute/subacutenecrosis of liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), chronic hepatitis/toxic hepatitis, liver abscess,hepatic coma, hepatorenal syndrome, other disorders of liver
  • Contraindication to spinal anesthesia technique (e.g., known spinal stenosis,coagulopathy, sepsis, infection at site of injection, uncooperative, refusal,anticoagulation medications not held within appropriate time frame*). *Per ASRAguidelines, Clopidogrel (Plavix) held for at least 7 days, Dabigatran (Pradexa) heldfor at least 5 days, Rivaroxaban (Xarelto)held for at least 3 days, Warfarin (Coumadin)held for at least 5 days or recent INR of less than 1.4, Enoxaparin (Lovenox) with doses > 1 mg/kg held for close to 24 hours.
  • Known to be currently pregnant or actively breastfeeding. Patients that have aprevious history of menopause, hysterectomy, or tubal ligation will not be required toperform a pregnancy test. Female patients that do not meet this criterion will beasked to submit a urine sample, and will require a negative urine sample in order toproceed with study protocol. Urine sample be collected pre-procedurally.
  • Impaired cognition

Study Design

Total Participants: 154
Study Start date:
February 25, 2019
Estimated Completion Date:
October 29, 2019

Connect with a study center

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.